Menu Search
Equities

Haemato AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0VZ7:LSE

Haemato AG

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta0.9443
Data delayed at least 20 minutes, as of Apr 10 2024.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Haemato AG, previously Windsor AG, is a Germany-based pharmaceutical company. The Company operates in two segments specialty pharma and lifestyle and aesthetics. Specialty pharma segment includes the trade and production of drugs and preparations in the field of human immunodeficiency virus (HIV), oncology, rheumatology, neurology as well as cardiovascular diseases and other chronic diseases. Its lifestyle and aesthetics segment is an outcome of new subsidiary M1 Aesthetics GmbH which is into marketing of pharmaceutical, medical and med tech products for aesthetic surgery and cosmetic dermatology. The Company acts as a wholesaler and parallel importer. Its business is carried out by there companies Haemato pharma AG, Haemato Med GmbH, M1 Aesthetics GmbH. It offers related support services.

  • Revenue in EUR (TTM)260.81m
  • Net income in EUR9.61m
  • Incorporated2003
  • Employees78.00
  • Location
    Haemato AGLilienthalstrasse 3aSCHOENEFELD 12529GermanyDEU
  • Phone+49 30 897308670
  • Fax+49 30 897308679
  • Websitehttps://haemato.de/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.